All In Biotech

Drug Trial Radar · NCT06383078

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

HR070803 in Combination With Oxaliplatin Plus Tegafur Versus HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate as Adjuvant Therapy for Pancreatic Cancer: A Multicenter, Multi-cohort, Randomized, Phase II Study

Last checked: Nov 19, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Apr 20, 2024

Primary completion

Mar 1, 2027

Study completion Dec 30, 2027

Sponsor

Sponsor type
Academic, hospital or other
First posted
Apr 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of HR070803 in Combination With Oxaliplatin plus Tegafur compared to HR070803 in combination with oxaliplatin, 5-fluorouracil/leucovorin (5FU/LV) treatment as adjuvant therapy in patients with resected pancreatic cancer.

Conditions

  • Efficacy and Safety

Interventions

  • HR070803Drug

    HR070803 60 mg/\^2 D1 over 90 minutes.

  • OxaliplatinDrug

    Oxaliplatin 85 mg/\^2 D1 over 2 hours.

  • TegafurDrug

    initial dose of S-1 is determined according to the body surface area,orally, D1-7.

  • Folinic acidDrug

    Folinic acid 400 mg/\^2 D1

  • 5-FluorouracilDrug

    5-FU 2400 mg/\^2 D1 IV continuous infusion over 46 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1-year Disease-free survival rateTime frame: Up to 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.